Artykuły w czasopismach na temat „Fu ci”
Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych
Sprawdź 50 najlepszych artykułów w czasopismach naukowych na temat „Fu ci”.
Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.
Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.
Przeglądaj artykuły w czasopismach z różnych dziedzin i twórz odpowiednie bibliografie.
Methot, N., i K. Basler. "Suppressor of fused opposes hedgehog signal transduction by impeding nuclear accumulation of the activator form of Cubitus interruptus". Development 127, nr 18 (15.09.2000): 4001–10. http://dx.doi.org/10.1242/dev.127.18.4001.
Pełny tekst źródłaZhou, Mengmeng, Yuhong Han, Bing Wang, Yong Suk Cho i Jin Jiang. "Dose-dependent phosphorylation and activation of Hh pathway transcription factors". Life Science Alliance 5, nr 11 (5.09.2022): e202201570. http://dx.doi.org/10.26508/lsa.202201570.
Pełny tekst źródłaKöhne, C.-H., J. Wils, M. Lorenz, P. Schöffski, R. Voigtmann, C. Bokemeyer, M. Lutz i in. "Randomized Phase III Study of High-Dose Fluorouracil Given As a Weekly 24-Hour Infusion With or Without Leucovorin Versus Bolus Fluorouracil Plus Leucovorin in Advanced Colorectal Cancer: European Organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952". Journal of Clinical Oncology 21, nr 20 (15.10.2003): 3721–28. http://dx.doi.org/10.1200/jco.2003.11.122.
Pełny tekst źródłaKabbinavar, Fairooz, Herbert I. Hurwitz, Louis Fehrenbacher, Neal J. Meropol, William F. Novotny, Grazyna Lieberman, Susan Griffing i Emily Bergsland. "Phase II, Randomized Trial Comparing Bevacizumab Plus Fluorouracil (FU)/Leucovorin (LV) With FU/LV Alone in Patients With Metastatic Colorectal Cancer". Journal of Clinical Oncology 21, nr 1 (1.01.2003): 60–65. http://dx.doi.org/10.1200/jco.2003.10.066.
Pełny tekst źródłaKu, Geoffrey Yuyat, Benjamin Haaland i Gilberto de Lima Lopes. "Cetuximab (C225) in the first-line treatment of advanced colorectal cancer (CRC) patients (Pts) with K-ras wild-type (WT) tumors: Does the choice and schedule of fluoropyrimidine (Fp) matter?" Journal of Clinical Oncology 30, nr 4_suppl (1.02.2012): 576. http://dx.doi.org/10.1200/jco.2012.30.4_suppl.576.
Pełny tekst źródłaWang-Gillam, Andrea, Chung-Pin Li, Gyorgy Bodoky, Andrew Dean, Yang-Shen Shan, Gayle S. Jameson, Teresa Macarulla i in. "Updated overall survival analysis of NAPOLI-1: Phase III study of nanoliposomal irinotecan (nal-IRI, MM-398), with or without 5-fluorouracil and leucovorin (5-FU/LV), versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy." Journal of Clinical Oncology 34, nr 4_suppl (1.02.2016): 417. http://dx.doi.org/10.1200/jco.2016.34.4_suppl.417.
Pełny tekst źródłaWagner, Anna D., Wilfried Grothe, Johannes Haerting, Gerhard Kleber, Axel Grothey i Wolfgang E. Fleig. "Chemotherapy in Advanced Gastric Cancer: A Systematic Review and Meta-Analysis Based on Aggregate Data". Journal of Clinical Oncology 24, nr 18 (20.06.2006): 2903–9. http://dx.doi.org/10.1200/jco.2005.05.0245.
Pełny tekst źródłaArkenau, Hendrik-Tobias, Dirk Arnold, Jim Cassidy, Eduardo Diaz-Rubio, Jean-Yves Douillard, Howard Hochster, Andrea Martoni i in. "Efficacy of Oxaliplatin Plus Capecitabine or Infusional Fluorouracil/Leucovorin in Patients With Metastatic Colorectal Cancer: A Pooled Analysis of Randomized Trials". Journal of Clinical Oncology 26, nr 36 (20.12.2008): 5910–17. http://dx.doi.org/10.1200/jco.2008.16.7759.
Pełny tekst źródłaNam, Ki-Woong, Chi Kyung Kim, Tae Jung Kim, Kyungmi Oh, Moon-Ku Han, Sang-Bae Ko i Byung-Woo Yoon. "FLAIR vascular hyperintensities predict early ischemic recurrence in TIA". Neurology 90, nr 9 (31.01.2018): e738-e744. http://dx.doi.org/10.1212/wnl.0000000000005034.
Pełny tekst źródłaPoplin, Elizabeth A., Jacqueline K. Benedetti, Norman C. Estes, Daniel G. Haller, Robert J. Mayer, Richard M. Goldberg, Geoffrey R. Weiss, Saul E. Rivkin i John S. Macdonald. "Phase III Southwest Oncology Group 9415/Intergroup 0153 Randomized Trial of Fluorouracil, Leucovorin, and Levamisole Versus Fluorouracil Continuous Infusion and Levamisole for Adjuvant Treatment of Stage III and High-Risk Stage II Colon Cancer". Journal of Clinical Oncology 23, nr 9 (20.03.2005): 1819–25. http://dx.doi.org/10.1200/jco.2005.04.169.
Pełny tekst źródłaSisson, Barbara E., Suzanne L. Ziegenhorn i Robert A. Holmgren. "Regulation of Ci and Su(fu) nuclear import in Drosophila". Developmental Biology 294, nr 1 (czerwiec 2006): 258–70. http://dx.doi.org/10.1016/j.ydbio.2006.02.050.
Pełny tekst źródłaSchilsky, Richard L., Jeremey Levin, William H. West, Alfred Wong, Bruce Colwell, Michael P. Thirlwell, Rafat H. Ansari i in. "Randomized, Open-Label, Phase III Study of a 28-Day Oral Regimen of Eniluracil Plus Fluorouracil Versus Intravenous Fluorouracil Plus Leucovorin as First-Line Therapy in Patients With Metastatic/Advanced Colorectal Cancer". Journal of Clinical Oncology 20, nr 6 (15.03.2002): 1519–26. http://dx.doi.org/10.1200/jco.2002.20.6.1519.
Pełny tekst źródłaHoning, Judith, Justin Smit, Christina Muijs, Johannes Burgerhof, Jannet Beukema, John Theodorus Plukker i Geke Hospers. "A comparison of carboplatin with paclitaxel and cisplatinum with 5-fluorouracil in definitive chemoradiotherapy in esophageal cancer patients." Journal of Clinical Oncology 32, nr 3_suppl (20.01.2014): 104. http://dx.doi.org/10.1200/jco.2014.32.3_suppl.104.
Pełny tekst źródłaSultana, Asma, Catrin Tudur Smith, David Cunningham, Naureen Starling, John P. Neoptolemos i Paula Ghaneh. "Meta-Analyses of Chemotherapy for Locally Advanced and Metastatic Pancreatic Cancer". Journal of Clinical Oncology 25, nr 18 (20.06.2007): 2607–15. http://dx.doi.org/10.1200/jco.2006.09.2551.
Pełny tekst źródłaRao, Sheela, Francesco Sclafani, Cathy Eng, Richard A. Adams, Marianne G. Guren, David Sebag-Montefiore, Al Benson i in. "International Rare Cancers Initiative Multicenter Randomized Phase II Trial of Cisplatin and Fluorouracil Versus Carboplatin and Paclitaxel in Advanced Anal Cancer: InterAAct". Journal of Clinical Oncology 38, nr 22 (1.08.2020): 2510–18. http://dx.doi.org/10.1200/jco.19.03266.
Pełny tekst źródłaSchmoll, Hans-Joachim, Josep Tabernero, Jean Alfred Maroun, Filippo G. De Braud, Timothy Jay Price, Eric Van Cutsem, Mark Hill, Silke Hoersch, Karen Rittweger i Daniel G. Haller. "Capecitabine plus oxaliplatin (XELOX) versus bolus 5-fluorouracil/leucovorin (5-FU/LV) as adjuvant therapy for stage III colon cancer: Survival follow-up of study NO16968 (XELOXA)." Journal of Clinical Oncology 30, nr 4_suppl (1.02.2012): 388. http://dx.doi.org/10.1200/jco.2012.30.4_suppl.388.
Pełny tekst źródłaDouillard, Jean-Yves, Paulo M. Hoff, Jamey R. Skillings, Peter Eisenberg, Neville Davidson, Peter Harper, Mark D. Vincent i in. "Multicenter Phase III Study of Uracil/Tegafur and Oral Leucovorin Versus Fluorouracil and Leucovorin in Patients With Previously Untreated Metastatic Colorectal Cancer". Journal of Clinical Oncology 20, nr 17 (1.09.2002): 3605–16. http://dx.doi.org/10.1200/jco.2002.04.123.
Pełny tekst źródłaYang Seoung Duk. "A Study on the Ci-Fu Thoughts of Xie-Ling-Yun". Journal of Chinese Language and Literature ll, nr 54 (grudzień 2009): 83–104. http://dx.doi.org/10.15792/clsyn..54.200912.83.
Pełny tekst źródłaYang, Seoung Duk. "A Study on The theory of Dong-Jin,s Ci-Fu". JOURNAL OF CHINESE HUMANITIES 76 (31.12.2020): 223–43. http://dx.doi.org/10.35955/jch.2020.12.76.223.
Pełny tekst źródłaCassidy, J., N. Scotto i E. Diaz-Rubio. "Review of completed and ongoing trials of capecitabine-based adjuvant therapy in patients with early-stage colon cancer." Journal of Clinical Oncology 29, nr 4_suppl (1.02.2011): 495. http://dx.doi.org/10.1200/jco.2011.29.4_suppl.495.
Pełny tekst źródłaMerchant, Mark, Felix F. Vajdos, Mark Ultsch, Henry R. Maun, Ulrich Wendt, Jennifer Cannon, William Desmarais, Robert A. Lazarus, Abraham M. de Vos i Frederic J. de Sauvage. "Suppressor of Fused Regulates Gli Activity through a Dual Binding Mechanism". Molecular and Cellular Biology 24, nr 19 (1.10.2004): 8627–41. http://dx.doi.org/10.1128/mcb.24.19.8627-8641.2004.
Pełny tekst źródłaMaisey, Nick, Ian Chau, David Cunningham, Andrew Norman, Matt Seymour, Tamas Hickish, Tim Iveson i in. "Multicenter Randomized Phase III Trial Comparing Protracted Venous Infusion (PVI) Fluorouracil (5-FU) With PVI 5-FU Plus Mitomycin in Inoperable Pancreatic Cancer". Journal of Clinical Oncology 20, nr 14 (15.07.2002): 3130–36. http://dx.doi.org/10.1200/jco.2002.09.029.
Pełny tekst źródłaBertagnolli, Monica M., Donna Niedzwiecki, Carolyn C. Compton, Hejin P. Hahn, Margaret Hall, Beatrice Damas, Scott D. Jewell i in. "Microsatellite Instability Predicts Improved Response to Adjuvant Therapy With Irinotecan, Fluorouracil, and Leucovorin in Stage III Colon Cancer: Cancer and Leukemia Group B Protocol 89803". Journal of Clinical Oncology 27, nr 11 (10.04.2009): 1814–21. http://dx.doi.org/10.1200/jco.2008.18.2071.
Pełny tekst źródłaWang-Gillam, Andrea, Richard Hubner, Beloo Mirakhur, Floris A. de Jong, Bruce Belanger i Li-Tzong Chen. "Dose modifications of liposomal irinotecan (nal-IRI) + 5-fluorouracil/leucovorin (5-FU/LV) in NAPOLI-1: Impact on efficacy." Journal of Clinical Oncology 36, nr 4_suppl (1.02.2018): 388. http://dx.doi.org/10.1200/jco.2018.36.4_suppl.388.
Pełny tekst źródłaTaïeb, Julien, Tim Maughan, Carsten Bokemeyer, Eric Van Cutsem, Thomas Brodowicz, Gunnar Folprecht, Regina Esser, Michael Schlichting i Josep Tabernero. "Cetuximab combined with infusional 5-fluorouracil/folinic acid (5-FU/FA) and oxaliplatin in metastatic colorectal cancer (mCRC): A pooled analysis of COIN and OPUS study data." Journal of Clinical Oncology 30, nr 15_suppl (20.05.2012): 3574. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.3574.
Pełny tekst źródłaWagner, A. D., W. Grothe, J. Haerting, G. Kleber, A. Grothey i W. E. Fleig. "Combination chemotherapies in advanced gastric cancer: An updated systematic review and meta-analysis". Journal of Clinical Oncology 25, nr 18_suppl (20.06.2007): 4555. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.4555.
Pełny tekst źródłaSchmoll, Hans-Joachim, Josep Tabernero, Jean Maroun, Filippo de Braud, Timothy Price, Eric Van Cutsem, Mark Hill, Silke Hoersch, Karen Rittweger i Daniel G. Haller. "Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial". Journal of Clinical Oncology 33, nr 32 (10.11.2015): 3733–40. http://dx.doi.org/10.1200/jco.2015.60.9107.
Pełny tekst źródłaSizer, B., A. Makris, C. Barone, P. Mainwaring i P. Eggleton. "QoL and resource use analysis of tegafur-uracil/LV or 5-FU/LV in first-line metastatic colorectal cancer (mCRC): Final results of a multicenter phase II study". Journal of Clinical Oncology 24, nr 18_suppl (20.06.2006): 3631. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.3631.
Pełny tekst źródłaKöhne, C. H., E. van Cutsem, J. Wils, C. Bokemeyer, M. El-Serafi, M. P. Lutz, M. Lorenz i in. "Phase III Study of Weekly High-Dose Infusional Fluorouracil Plus Folinic Acid With or Without Irinotecan in Patients With Metastatic Colorectal Cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986". Journal of Clinical Oncology 23, nr 22 (1.08.2005): 4856–65. http://dx.doi.org/10.1200/jco.2005.05.546.
Pełny tekst źródłaPeng, Chengwei, Saad Saffo, Michael Shusterman, Daniel Jacob Becker, Jordan Berlin, Paul Eliezer Oberstein, Anil Nagar i Shun Yu. "Analysis of the impact of eliminating bolus 5-fluorouracil in metastatic colorectal cancer." Journal of Clinical Oncology 41, nr 4_suppl (1.02.2023): 59. http://dx.doi.org/10.1200/jco.2023.41.4_suppl.59.
Pełny tekst źródłaFuchs, Charles S., Donna Niedzwiecki, Harvey J. Mamon, Joel E. Tepper, Xing Ye, Richard S. Swanson, Peter C. Enzinger i in. "Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance)". Journal of Clinical Oncology 35, nr 32 (10.11.2017): 3671–77. http://dx.doi.org/10.1200/jco.2017.74.2130.
Pełny tekst źródłaLi, Jia-yi, Xuan-zhang Huang, Peng Gao, Xiao-wan Chen, Yong-xi Song, Xing-er Lv, Yv Fu, Qiong Xiao i Zhen-ning Wang. "Postoperative Adjuvant Treatment Strategy for Locally Advanced Rectal Cancer after Neoadjuvant Treatment". BioMed Research International 2021 (27.03.2021): 1–21. http://dx.doi.org/10.1155/2021/8852699.
Pełny tekst źródłaWang, Aiqing. "Cliché-ridden Online Danmei Fiction? A Case Study of Tianguan ci fu". Acta Asiatica Varsoviensia 35 (2022): 281–314. http://dx.doi.org/10.60018/acasva.iray5065.
Pełny tekst źródłaSchmidt, Jan, Ulrich Abel, Jürgen Debus, Sabine Harig, Katrin Hoffmann, Thomas Herrmann, Detlef Bartsch i in. "Open-Label, Multicenter, Randomized Phase III Trial of Adjuvant Chemoradiation Plus Interferon Alfa-2b Versus Fluorouracil and Folinic Acid for Patients With Resected Pancreatic Adenocarcinoma". Journal of Clinical Oncology 30, nr 33 (20.11.2012): 4077–83. http://dx.doi.org/10.1200/jco.2011.38.2960.
Pełny tekst źródłaModest, Dominik Paul, Meinolf Karthaus, Stefan Fruehauf, Ullrich Graeven, Lothar Müller, Alexander Koenig, Ludwig Fischer von Weikersthal i in. "FU/FA maintenance therapy with or without panitumumab (pmab) in RAS wild-type metastatic colorectal cancer (mCRC) (PanaMa, AIO KRK 0212): Updated efficacy analyses." Journal of Clinical Oncology 42, nr 16_suppl (1.06.2024): 3506. http://dx.doi.org/10.1200/jco.2024.42.16_suppl.3506.
Pełny tekst źródłaYothers, Greg, Patricia A. Ganz, Samia H. Lopa, Clifford Y. Ko, D. Lawrence Wickerham i Norman Wolmark. "Patient-reported outcomes (PROs) comparison of 5-FU and capecitabine (cape) with concurrent radiotherapy (RT) for neoadjuvant treatment of rectal cancer: Results of NSABP R-04." Journal of Clinical Oncology 30, nr 4_suppl (1.02.2012): 391. http://dx.doi.org/10.1200/jco.2012.30.4_suppl.391.
Pełny tekst źródłaSargent, Daniel J., Silvia Marsoni, Genevieve Monges, Stephen N. Thibodeau, Roberto Labianca, Stanley R. Hamilton, Amy J. French i in. "Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer". Journal of Clinical Oncology 28, nr 20 (10.07.2010): 3219–26. http://dx.doi.org/10.1200/jco.2009.27.1825.
Pełny tekst źródłaLiu, Guo-Chen, Jun-Ping Yan, Qing He, Xin An, Zhi-Zhong Pan i Pei-Rong Ding. "Effect of Neoadjuvant Chemoradiotherapy with Capecitabine versus Fluorouracil for Locally Advanced Rectal Cancer: A Meta-Analysis". Gastroenterology Research and Practice 2016 (2016): 1–10. http://dx.doi.org/10.1155/2016/1798285.
Pełny tekst źródłaFreeman, Karoline, Martin Connock, Ewen Cummins, Tara Gurung, Sian Taylor-Phillips, Rachel Court, Mark Saunders, Aileen Clarke i Paul Sutcliffe. "Fluorouracil plasma monitoring: systematic review and economic evaluation of the My5-FU assay for guiding dose adjustment in patients receiving fluorouracil chemotherapy by continuous infusion". Health Technology Assessment 19, nr 91 (listopad 2015): 1–322. http://dx.doi.org/10.3310/hta19910.
Pełny tekst źródłaZafar, Amna, Zsofia D. Drobni, Matthew Lei, Carlos A. Gongora, Thiago Quinaglia, Uvette Y. Lou, Ramya Mosarla i in. "The efficacy and safety of cardio-protective therapy in patients with 5-FU (Fluorouracil)-associated coronary vasospasm". PLOS ONE 17, nr 4 (7.04.2022): e0265767. http://dx.doi.org/10.1371/journal.pone.0265767.
Pełny tekst źródłaIkawati, Muthi, i Endah Puji Septisetyani. "Pentagamavunone-0 (PGV-0), a Curcumin Analog, Enhances Cytotoxicity of 5-Fluorouracil and Modulates Cell Cycle in WiDr Colon Cancer Cells". Indonesian Journal of Cancer Chemoprevention 9, nr 1 (28.02.2018): 23. http://dx.doi.org/10.14499/indonesianjcanchemoprev9iss1pp23-31.
Pełny tekst źródłaSholihah, Imroatus, Meirizky Zulharini S., Amalia Miranda, Refki Riswansyah i Riris Istighfari Jenie. "Jure Leaf Extract (Nerium indium Mill.) Increased 5-Fluorouracil Sensitivity through Inhibition of NF-κB Activation and Transporter Protein in WiDr Colon Cancer Cell". Indonesian Journal of Cancer Chemoprevention 7, nr 3 (1.02.2017): 87. http://dx.doi.org/10.14499/indonesianjcanchemoprev7iss3pp87-92.
Pełny tekst źródłaAl-Thani, Hassan, Ayman El-Menyar, Valsa Koshy, Ahmed Hussein, Ahmed Sharaf, Mohammad Asim i Ahmed Sadek. "Implications of Foot Ulceration in Hemodialysis Patients: A 5-Year Observational Study". Journal of Diabetes Research 2014 (2014): 1–6. http://dx.doi.org/10.1155/2014/945075.
Pełny tekst źródłaMohamed, Yehia I., Aliya Qayyum, Manal Hassan, Lianchun Xiao, Dan G. Duda, Rikita Hatia, Sunyoung S. Lee i in. "Treatment outcome and prognostic indicators in 26 cases of fibrolamellar hepatocellular carcinoma under interferon based therapy." Journal of Clinical Oncology 38, nr 15_suppl (20.05.2020): e16626-e16626. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.e16626.
Pełny tekst źródłaHaller, Daniel G., Josep Tabernero, Jean Maroun, Filippo de Braud, Timothy Price, Eric Van Cutsem, Mark Hill, Frank Gilberg, Karen Rittweger i Hans-Joachim Schmoll. "Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer". Journal of Clinical Oncology 29, nr 11 (10.04.2011): 1465–71. http://dx.doi.org/10.1200/jco.2010.33.6297.
Pełny tekst źródłaBang, Kyunghye, Jaekyung Cheon, Jae Ho Jeong, Hyeon-Su Im, Kyu-Pyo Kim, Baek-Yeol Ryoo i Changhoon Yoo. "Efficacy and safety of liposomal irinotecan plus fluorouracil/leucovorin after progression on conventional irinotecan-containing chemotherapy for metastatic pancreatic adenocarcinoma." Journal of Clinical Oncology 39, nr 3_suppl (20.01.2021): 382. http://dx.doi.org/10.1200/jco.2021.39.3_suppl.382.
Pełny tekst źródłaBang, Kyunghye, Jaekyung Cheon, Jae Ho Jeong, Hyeon-Su Im, Kyu-pyo Kim, Baek-Yeol Ryoo i Changhoon Yoo. "Clinical outcomes of liposomal irinotecan plus fluorouracil/leucovorin for metastatic pancreatic adenocarcinoma in patients previously treated with conventional irinotecan-containing chemotherapy". Therapeutic Advances in Medical Oncology 13 (styczeń 2021): 175883592110030. http://dx.doi.org/10.1177/17588359211003053.
Pełny tekst źródłaMcCaffrey, J. A., S. Hilton, M. Mazumdar, S. Sadan, M. Heineman, J. Hirsch, W. K. Kelly, H. I. Scher i D. F. Bajorin. "Phase II randomized trial of gallium nitrate plus fluorouracil versus methotrexate, vinblastine, doxorubicin, and cisplatin in patients with advanced transitional-cell carcinoma." Journal of Clinical Oncology 15, nr 6 (czerwiec 1997): 2449–55. http://dx.doi.org/10.1200/jco.1997.15.6.2449.
Pełny tekst źródłaTesta, Luca, Azeem Latib, Nedy Brambilla, Federico De Marco, Claudia Fiorina, Marianna Adamo, Cristina Giannini i in. "Long-term clinical outcome and performance of transcatheter aortic valve replacement with a self-expandable bioprosthesis". European Heart Journal 41, nr 20 (6.01.2020): 1876–86. http://dx.doi.org/10.1093/eurheartj/ehz925.
Pełny tekst źródłaHendlisz, Alain, Marc Van den Eynde, Marc Peeters, Geert Maleux, Bieke Lambert, Jaarke Vannoote, Katrien De Keukeleire i in. "Phase III Trial Comparing Protracted Intravenous Fluorouracil Infusion Alone or With Yttrium-90 Resin Microspheres Radioembolization for Liver-Limited Metastatic Colorectal Cancer Refractory to Standard Chemotherapy". Journal of Clinical Oncology 28, nr 23 (10.08.2010): 3687–94. http://dx.doi.org/10.1200/jco.2010.28.5643.
Pełny tekst źródła